<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <title>Specific Aims – PromptGenix SBIR Phase I</title>
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <style>
    body {
      margin: 40px;
      font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", sans-serif;
      color: #111827;
      line-height: 1.45;
    }

    h1 {
      font-size: 1.4rem;
      margin-bottom: 6px;
    }

    h2 {
      font-size: 1rem;
      margin-top: 18px;
      margin-bottom: 4px;
      letter-spacing: 0.08em;
    }

    p {
      font-size: 0.92rem;
      margin: 6px 0;
    }

    ul {
      margin: 6px 0 6px 18px;
      padding: 0;
      font-size: 0.92rem;
    }

    li {
      margin-bottom: 4px;
    }

    .header {
      margin-bottom: 16px;
    }

    .meta {
      font-size: 0.82rem;
      color: #374151;
    }

    .box {
      border: 1px solid #d1d5db;
      border-radius: 8px;
      padding: 10px 12px;
      margin-top: 8px;
      font-size: 0.9rem;
      background: #f9fafb;
    }

    .footer-note {
      font-size: 0.78rem;
      color: #4b5563;
      margin-top: 12px;
    }
  </style>
</head>
<body>

  <div class="header">
    <h1>Specific Aims (Phase I): PromptGenix – BioAI Automation Platform</h1>
    <div class="meta">
      PromptGenix LLC (Women & Minority-Owned)<br/>
      Contact: dohoon.kim1@icloud.com<br/>
      Website: https://promptgenix.org/sbir.html
    </div>
  </div>

  <h2>SIGNIFICANCE</h2>
  <p>
    Immunology and infectious disease research programs routinely generate large volumes of RNA-Seq,
    single-cell RNA-Seq, and high-dimensional flow cytometry data. Despite major advances in data generation,
    biological insight remains a bottleneck. Analysis workflows are fragmented across tools, rely heavily on
    custom scripts, and require scarce bioinformatics expertise. As a result, turnaround times are long,
    reproducibility is inconsistent, and interpretation often depends on manual literature review by
    overextended investigators.
  </p>
  <p>
    This gap directly limits the speed and quality of hypothesis generation, experimental design, and
    decision-making in NIH-funded studies, particularly in resource-constrained academic and government laboratories.
  </p>

  <h2>INNOVATION</h2>
  <p>
    PromptGenix introduces an integrated BioAI co-investigator that combines end-to-end automated omics
    pipelines with a literature-aware internal LLM Hypothesis Generator.
  </p>
  <p>
    Unlike existing platforms that stop at statistical results or static summaries, PromptGenix produces
    ranked, testable biological hypotheses and concrete follow-up experiment suggestions grounded in
    traceable PubMed-aware reasoning.
  </p>

  <h2>OVERALL OBJECTIVE &amp; CENTRAL HYPOTHESIS</h2>
  <div class="box">
    <p><strong>Objective:</strong> Deliver a validated Phase I prototype that automates RNA-Seq and flow
    cytometry workflows and generates reviewer-ready reports with ranked biological hypotheses and suggested
    validation experiments.</p>
    <p><strong>Central hypothesis:</strong> Standardized, reproducible pipelines combined with traceable,
    literature-aware LLM reasoning will reduce analysis turnaround time and increase interpretability,
    enabling faster and higher-quality study decisions in immunology and infectious disease research.</p>
  </div>

  <h2>SPECIFIC AIMS</h2>
  <ul>
    <li>
      <strong>Aim 1.</strong> Harden end-to-end automated RNA-Seq and flow cytometry pipelines using public
      datasets (GEO, SRA, FlowRepository).
    </li>
    <li>
      <strong>Aim 2.</strong> Implement a traceable Hypothesis Generator that ranks biological hypotheses
      and proposes validation experiments using PubMed-aware reasoning.
    </li>
    <li>
      <strong>Aim 3.</strong> Generate exportable HTML/PDF reports and evaluate usability through 2–3 pilot
      studies using public or de-identified datasets.
    </li>
  </ul>

  <h2>EXPECTED OUTCOMES &amp; DELIVERABLES</h2>
  <ul>
    <li>Validated prototype producing reproducible, versioned outputs across reruns</li>
    <li>Reviewer-ready reports generated within &lt;24 hours from raw data inputs</li>
    <li>Measured reductions in turnaround time and positive user feedback on AI-generated hypotheses</li>
  </ul>

  <h2>IMPACT</h2>
  <p>
    Successful completion of Phase I will establish PromptGenix as a scalable BioAI co-investigator platform
    for immunology and infectious disease research. Phase I validation will rely exclusively on public
    datasets to avoid IP or data-use conflicts and will position the platform for Phase II expansion into
    multi-site studies and secure deployments.
  </p>

  <div class="footer-note">
    Phase I SBIR – NIH/NIAID focus · Public-data validation · Women & Minority-Owned Small Business
  </div>

</body>
</html>
